Regulatoriskt pressmeddelande

Oncopeptides announces Q4 2025 sales and updates cash-flow expectations

Stockholm, January 15, 2026 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the net sales for the fourth quarter of 2025 and updates its cash-flow expectations.

Full-year sales of Pepaxti more than doubled in 2025 with the company´s launch in Italy exceeding expectations. The growth rate has been negatively impacted by slower-than-expected uptake in Germany during the second half of 2025 and in Spain during the fourth quarter due to a strike among medical doctors.

· Based on unaudited figures, Oncopeptides expects Q4 net sales to amount to 18.6 million SEK, an increase of 88 percent versus Q4 2024 and full year 2025 sales to amount to 71.2 million SEK, an increase of 125 percent versus 2024.
· The company expects positive cash-flow to occur in 2027, instead of end of the previously communicated 2026.

“We remain confident in Pepaxti and our science, and we are focused on exploring complementary initiatives to compensate for the slower-than-expected sales growth, including strategic measures in Germany, the partnership discussions with a potential partner in Japan, opportunities for Pepaxti in Europe outside our key markets and exploring the emerging opportunity in Glioblastoma for our pipeline asset OPD5,” says Sofia Heigis, CEO of Oncopeptides.

As a consequence of the increasingly limited access to healthcare professionals in Germany, Oncopeptides has performed a strategic review of its German commercialization strategy to sharpen focus and reach profitability on a country level during 2026. The company continues to review the strategic direction of the company and its financial position, including exploration of alternative options for funding beyond Pepaxti revenue in the company´s European key markets, including but not limited to the potential licensing deal in Japan, other Pepaxti partnering options and partnerships for one of Oncopeptides’ pipeline assets.

Update on Japan
As first communicated during the first quarter 2025, Oncopeptides is involved in partnership negotiations for Japan. The Company has focused its negotiations to one well-established sizeable Japanese pharma company from which the company has received a non-binding offer for the licensing of Pepaxti for the Japanese market and have recently progressed into contracting discussions.

Webcast for investors
The company will host a webcast and Q&A session aimed at investors, analysts and media tomorrow, Friday, January 16 at 09.00 CET.

If you wish to participate via webcast, please use the link below.
https://oncopeptides.events.inderes.com/investor-conference-2026

If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.inderes.com/teleconference/?id=5005873

Full end-of-year report
The full 2025 end of year report will be published on February 19 followed by a webcast and Q&A session on the same day. Invitation to follow.

About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

About Pepaxti
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.